Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC "unfairness" standard

This article was originally published in The Tan Sheet

Executive Summary

Nonprescription Drug Manufacturers Association is part of a 36-member coalition that sent a Feb. 15 letter to all conferees working on Federal Trade Commission reauthorization legislation (HR 2243). The letter, also signed by the Cosmetic, Toiletry and Fragrance Association, urges support of "continued restrictions on the FTC's unfairness authority for advertising" and supports a Senate version of the bill, which makes permanent a ban on FTC's use of unfairness rulemaking authority for ads. The House bill places no restrictions on FTC's rulemaking authority ("The Tan Sheet" Sept. 27, 1993, In Brief)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS082511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel